Ontario Drug Benefit Formulary/Comparative Drug Index

Similar documents
Ontario Drug Benefit Formulary/Comparative Drug Index

Ontario Drug Benefit Formulary/ Comparative Drug Index

Ontario Drug Benefit Formulary/Comparative Drug Index

Ontario Drug Benefit Formulary/Comparative Drug Index

UPDATE AF Ontario Drug Benefit Formulary/Comparative Drug Index No. 41 Effective March 26, 2012 SUMMARY OF CHANGES

Ontario Drug Benefit Formulary/Comparative Drug Index

Ontario Drug Benefit Formulary/Comparative Drug Index

Ontario Drug Benefit Formulary/Comparative Drug Index

Ontario Drug Benefit Formulary/Comparative Drug Index

Ontario Drug Benefit Formulary/Comparative Drug Index

Ontario Drug Benefit Formulary/Comparative Drug Index

Ontario Drug Benefit Formulary/ Comparative Drug Index

Ontario Drug Benefit Formulary/Comparative Drug Index

Ontario Drug Benefit Formulary/Comparative Drug Index

Ontario Drug Benefit Formulary/Comparative Drug Index

UPDATE AX Ontario Drug Benefit Formulary/Comparative Drug Index No. 41 Effective August 29, 2013 SUMMARY OF CHANGES

UPDATE E Ontario Drug Benefit Formulary/Comparative Drug Index No. 41 Effective December 23, 2008 SUMMARY OF CHANGES

Ontario Drug Benefit Formulary/Comparative Drug Index

UPDATE AU Ontario Drug Benefit Formulary/Comparative Drug Index No. 41 Effective May 31, 2013 SUMMARY OF CHANGES

UPDATE AA Ontario Drug Benefit Formulary/Comparative Drug Index No. 41 Effective September 15, 2011 SUMMARY OF CHANGES

Ontario Drug Benefit Formulary/Comparative Drug Index

Ontario Drug Benefit Formulary/Comparative Drug Index

Ontario Drug Benefit Formulary/Comparative Drug Index

Ontario Drug Benefit Formulary/Comparative Drug Index

UPDATE AB Ontario Drug Benefit Formulary/Comparative Drug Index No. 41 Effective October 25, 2011 SUMMARY OF CHANGES

Ontario Drug Benefit Formulary/Comparative Drug Index

Ontario Drug Benefit Formulary/Comparative Drug Index

Ontario Drug Benefit Formulary/Comparative Drug Index

UPDATE AJ Ontario Drug Benefit Formulary/Comparative Drug Index No. 41 Effective July 27, 2012 SUMMARY OF CHANGES

UPDATE C Ontario Drug Benefit Formulary/Comparative Drug Index No. 41 Effective November 04, 2008 SUMMARY OF CHANGES

BULLETIN # 89. Manitoba Drug Benefits and Interchangeability Formulary Amendments. The following amendments will take effect on October 20, 2016

UPDATE AZ Ontario Drug Benefit Formulary/Comparative Drug Index No. 41 Effective October 31, 2013 SUMMARY OF CHANGES

UPDATE B Ontario Drug Benefit Formulary/Comparative Drug Index No. 41 Effective October 01, 2008 SUMMARY OF CHANGES

BULLETIN # 74. Manitoba Drug Benefits and Interchangeability Formulary Amendments. The following amendments will take effect on October 17, 2013

Ontario Drug Benefit Formulary/Comparative Drug Index

NB Drug Plans Formulary Update

UPDATE F Ontario Drug Benefit Formulary/Comparative Drug Index No. 41 Effective 30 January, 2009 SUMMARY OF CHANGES

Nova Scotia Pharmacare Programs Interchangeable Product Updates November 13, 2018 New Categories

Updates to the Alberta Drug Benefit List. Effective October 1, 2017

NB Drug Plans Formulary Update

Non-Insured Health Benefits

Ontario Drug Benefit Formulary/Comparative Drug Index

Therapeutic Substitution Service - Proton Pump Inhibitors (PPIs)

UPDATE AE Ontario Drug Benefit Formulary/Comparative Drug Index No. 41 Effective February 29, 2012 SUMMARY OF CHANGES

NB Drug Plans Formulary Update

Manager, PEI Drug Programs Date : December 7, 2009 Tel / Tél : (902) Fax / Téléc : (902)

New Interchangeable Products Approved and Benefit Status Within the Nova Scotia Pharmacare Programs March 2016

Updates to the Alberta Human Services Drug Benefit Supplement

Mifegymiso. New Exception Status Benefits

SASKATCHEWAN FORMULARY BULLETIN. Update to the 60th Edition of the Saskatchewan Formulary

Ontario Drug Benefit Formulary/ Comparative Drug Index

NB Drug Plans Formulary Update

BULLETIN # 90. Manitoba Drug Benefits and Interchangeability Formulary Amendments. The following amendments will take effect on January 25, 2017

BULLETIN # 84. Manitoba Drug Benefits and Interchangeability Formulary Amendments. The following amendments will take effect on October 22, 2015

New Exception Status Benefits

SASKATCHEWAN FORMULARY COMMITTEE UPDATE BULLETIN TO THE 55th EDITION OF THE SASKATCHEWAN FORMULARY

SASKATCHEWAN FORMULARY BULLETIN Update to the 60th Edition of the Saskatchewan Formulary

BULLETIN # 98. Manitoba Drug Benefits and Interchangeability Formulary Amendments. The following amendments will take effect on April 19, 2018

BULLETIN # 78. Manitoba Drug Benefits and Interchangeability Formulary Amendments. The following amendments will take effect on July 17, 2014

UPDATE C Ontario Drug Benefit Formulary/Comparative Drug Index No. 41 Effective November 04, 2008 SUMMARY OF CHANGES

SASKATCHEWAN FORMULARY COMMITTEE BULLETIN FOR THE UPDATE TO THE 56th EDITION OF THE SASKATCHEWAN FORMULARY

NBPDP Formulary Update

BULLETIN # 79. Manitoba Drug Benefits and Interchangeability Formulary Amendments. The following amendments will take effect on October 16, 2014

New Exception Status Benefits

BENEFIT CHANGES TO NBPDP

UPDATE Z Ontario Drug Benefit Formulary/Comparative Drug Index No. 41 Effective August 04, 2011 SUMMARY OF CHANGES

DOD PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL

Geriatric Pharmacology. Kwi Bulow, M.D. Clinical Professor of Medicine Director, Academic Geriatric Resource Center

BULLETIN # 80. Manitoba Drug Benefits and Interchangeability Formulary Amendments. The following amendments will take effect on January 19, 2015

Non-Insured Health Benefits

Updates to the Alberta Drug Benefit List. Effective December 1, 2018

NB Drug Plans Formulary Update

Updates to the Alberta Drug Benefit List. Effective June 1, 2018

Updates to the Alberta Drug Benefit List. Effective February 1, 2018

Archived Content. This content was archived on June 24, 2013.

Non-Insured Health Benefits

20:00. Blood Formulation, Coagulation and Thrombosis. 20:00 Blood Formulation, Coagulation and Thrombosis

SASKATCHEWAN FORMULARY COMMITTEE UPDATE BULLETIN 52nd Edition

SASKATCHEWAN FORMULARY COMMITTEE UPDATE BULLETIN 51st Edition

SASKATCHEWAN FORMULARY COMMITTEE BULLETIN TO THE 58th EDITION OF THE SASKATCHEWAN FORMULARY

Pharmacy Consultant, PEI Drug Programs Date : September 8, 2009 Tel / Tél : (902) Fax / Téléc : (902)

Treatment for Overactive Bladder

New Exception Status Benefits

BULLETIN # 101. Manitoba Drug Benefits and Interchangeability Formulary Amendments. The following amendments will take effect on October 18, 2018

NEUROPATHIC CANCER PAIN STANDARDS AND GUIDELINES

DOD PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL

STEP THERAPY PROGRAM

levetiracetam 250,500,750 and 1000mg tablets and levetiracetam oral solution 100mg/1ml (Keppra ) (No. 397/07) UCB Pharma Ltd

Dementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist

FirstCarolinaCare Insurance Company. Step Therapy Requirements

Santa Clara Family Health Plan Cal MediConnect Formulary. List of Step Therapy Requirements Effective: 12/01/ E

AMANTADINE ER. Products Affected Step 2: OSMOLEX ER 129 MG TABLET, EXTENDED RELEASE OSMOLEX ER 193 MG TABLET, Details

ANTICONVULSANTS. Details

ANTICONVULSANTS. Details

Overactive bladder (OAB) affects approximately 15% of the adult population. Diagnosis is based

Changes in Benefit Status and Criteria Update: Topiramate

SASKATCHEWAN FORMULARY COMMITTEE BULLETIN 55th EDITION

SASKATCHEWAN FORMULARY COMMITTEE BULLETIN FOR THE UPDATE TO THE 56th EDITION OF THE SASKATCHEWAN FORMULARY

Transcription:

Ministry of Health and Long-Term Care Ontario Drug Benefit Formulary/Comparative Drug Index Edition 42 Summary of Changes July 2016 Effective July 28, 2016 Drug Programs Policy and Strategy Branch Ontario Public Drug Programs Ministry of Health and Long-Term Care

Table of Contents New Single Source Product... 3 New Multi-Source Products... 4 New Off-Formulary Interchangeable (OFI) Products... 8 Status Change from Off-Formulary Interchangeable Products to Limited Use... 9 Off-Formulary Interchangeable Products Delisted... 10 Drug Benefit Price (DBP) Changes... 11 OFI Product Price Changes... 12 Product Manufacturer Name Changes... 13 Product Brand and Manufacturer Name Changes... 14 Discontinued Products... 15 Delisted Products... 16 2

New Single Source Product DIN/PIN PRODUCT NAME,STRENGTH & DOSAGE FORM GENERIC NAME MFR DBP 02439611 Humalog 200 units/ml INSULIN LISPRO LIL 102.8800 KwikPen 200U/mL Inj Sol-Pref Pen 5x3mL Pk Therapeutic Note: Note: For the treatment of patients with Type 1 diabetes mellitus. For the treatment of patients with Type 2 diabetes mellitus using insulin in an intensive regimen with 3 or more injections per day or an insulin pump. For the treatment of patients with Type 2 diabetes mellitus who are either experiencing recurrent hypoglycemia OR are unable to achieve adequate post-prandial glucose control while on less intensive regimen of regular insulin (1-2 injections per day). 3

New Multi-Source Products DIN/PIN BRAND NAME STRENGTH DOSAGE FORM MFR DBP 02331284 Amlodipine 5mg Tab SAI 0.2417 02331292 Amlodipine 10mg Tab SAI 0.3587 (Interchangeable with Norvasc) DIN/PIN BRAND NAME STRENGTH DOSAGE FORM MFR DBP 02439654 Act Bupropion XL 150mg ER Tab ACV 0.2926 02439662 Act Bupropion XL 300mg ER Tab ACV 0.5853 (Interchangeable with Wellbutrin XL) Reason For Use Code and Clinical Criteria Code 315 For the treatment of depression. LU Authorization Period: Indefinite. 4

New Multi-Source Products (Cont d...) DIN/PIN BRAND NAME STRENGTH DOSAGE FORM MFR DBP 02445670 Auro-Celecoxib 100mg Cap AUR 0.1776 02445689 Auro-Celecoxib 200mg Cap AUR 0.3553 (Interchangeable with Celebrex) Reason For Use Code and Clinical Criteria Osteoarthritis Code 316 For patients who have failed an adequate trial of acetaminophen (e.g. acetaminophen 1g QID for several weeks) and have had: History of a documented, clinically significant ulcer or GI bleed; or Failure or intolerance to at least three listed NSAIDS. NOTE: The maximum daily dose of celecoxib which will be reimbursed for the treatment of osteoarthritis is 200mg. LU Authorization Period: 1 year. Rheumatoid arthritis Code 317 For patients who have had: History of a documented, clinically significant ulcer or GI bleed; or Failure or intolerance to at least three listed NSAIDS. NOTE: The maximum daily dose of celecoxib which will be reimbursed for the treatment of rheumatoid arthritis is 400mg. LU Authorization Period: 1 year. DIN/PIN BRAND NAME STRENGTH DOSAGE FORM MFR DBP 02451913 Jamp-Duloxetine 30mg DR Cap JPC 0.4814 02451921 Jamp-Duloxetine 60mg DR Cap JPC 0.9769 (Interchangeable with Cymbalta) 5

New Multi-Source Products (Cont d...) DIN/PIN BRAND NAME STRENGTH DOSAGE FORM MFR DBP 02452359 Nat-Granisetron 1mg Tab NAT 9.0000 (Interchangeable with Kytril) Reason For Use Code and Clinical Criteria Code 91 For the treatment of emesis in cancer patients receiving highly emetogenic chemotherapy. LU Authorization Period: 1 year. Code 92 For patients receiving intravenous chemotherapy or radiation therapy who have not experienced adequate control with other available anti-emetics. LU Authorization Period: 1 year. Code 93 For patients receiving intravenous chemotherapy or radiation therapy who experience intolerable side effects with other anti- emetics. LU Authorization Period: 1 year. Code 326 For the treatment of emesis in patients receiving radiation therapy which consists of single fraction treatment to the abdominal cavity, hemi-body irradiation and total body irradiation. NOTE: The therapeutic value of GRANISETRON HCL more than 24 hours after the last dose of chemotherapy is unproven. LU Authorization Period: 1 year. Code 454 For the treatment of emesis in cancer patients receiving moderately emetogenic chemotherapy (MEC) regimens. LU Authorization Period: 1 year. 6

New Multi-Source Products (Cont d...) DIN/PIN BRAND NAME STRENGTH DOSAGE FORM MFR DBP 02353547 Sertraline 100mg Cap SAI 0.4458 (Interchangeable with Zoloft) DIN/PIN BRAND NAME STRENGTH DOSAGE FORM MFR DBP 02428911 Med-Solifenacin 5mg Tab GMP 0.4223 02428938 Med-Solifenacin 10mg Tab GMP 0.4223 (Interchangeable with Vesicare) Reason For Use Code and Clinical Criteria Code 290 For patients with urinary frequency, urgency or urge incontinence who have: Failed to respond to behavioral techniques AND an adequate trial of oxybutynin with gradual dose escalation has shown to be either ineffective or resulted in unacceptable side effects. NOTE: If after a trial of 2 weeks patients continue to experience similar side effects and no greater efficacy than oxybutynin, continued therapy with this more costly agent should be reassessed. Antimuscarinic agents should be used with caution in the elderly due to potentially serious adverse effects (e.g. confusion, psychosis, acute urinary retention, constipation). Antimuscarinic agents should be avoided in older adults with pre-existing cognitive impairment (e.g. dementia) and those who are already using other drugs with significant anticholinergic effects (e.g. tricyclic antidepressants) in order to avoid a high overall anticholinergic drug burden. LU Authorization Period: Indefinite. 7

New Off-Formulary Interchangeable (OFI) Products DIN/PIN BRAND NAME STRENGTH DOSAGE FORM MFR UNIT COST 02447851 Buspirone 10mg Tab SAI 0.6521 (Interchangeable with Buspar) DIN/PIN BRAND NAME STRENGTH DOSAGE FORM MFR UNIT COST 02418436 Teva-Rasagiline 0.5mg Tab TEV 6.1285 02418444 Teva-Rasagiline 1mg Tab TEV 6.1285 (Interchangeable with Azilect) 8

Status Change from Off-Formulary Interchangeable Products to Limited Use DIN/PIN BRAND NAME STRENGTH DOSAGE FORM MFR DBP 02274183 Act Levetiracetam 250mg Tab ACV 0.4459 02274191 Act Levetiracetam 500mg Tab ACV 0.5432 02274205 Act Levetiracetam 750mg Tab ACV 0.7523 02285924 Apo-Levetiracetam 250mg Tab APX 0.4459 02285932 Apo-Levetiracetam 500mg Tab APX 0.5432 02285940 Apo-Levetiracetam 750mg Tab APX 0.7523 02375249 Auro-Levetiracetam 250mg Tab AUR 0.4459 02375257 Auro-Levetiracetam 500mg Tab AUR 0.5432 02375265 Auro-Levetiracetam 750mg Tab AUR 0.7523 02403005 Jamp-Levetiracetam 250mg Tab JPC 0.4459 02403021 Jamp-Levetiracetam 500mg Tab JPC 0.5432 02403048 Jamp-Levetiracetam 750mg Tab JPC 0.7523 02440202 Nat-Levetiracetam 250mg Tab NAT 0.4459 02440210 Nat-Levetiracetam 500mg Tab NAT 0.5432 02440229 Nat-Levetiracetam 750mg Tab NAT 0.7523 02396106 Ran-Levetiracetam 250mg Tab RAN 0.4459 02396114 Ran-Levetiracetam 500mg Tab RAN 0.5432 02396122 Ran-Levetiracetam 750mg Tab RAN 0.7523 02247027 Keppra 250mg Tab UCB 1.7836 02247028 Keppra 500mg Tab UCB 2.1725 02247029 Keppra 750mg Tab UCB 3.0089 Reason For Use Code and Clinical Criteria Code 473 As adjunctive therapy in the management of patients with epilepsy who are not satisfactorily controlled by at least 2 other General Benefit anticonvulsant therapies (e.g., phenytoin, carbamazepine, gabapentin, lamotrigine, topiramate, etc.); AND patients are under the care of a physician experienced in the treatment of epilepsy. LU Authorization Period: Indefinite. 9

Off-Formulary Interchangeable Products Delisted DIN/PIN BRAND NAME STRENGTH DOSAGE FORM MFR 02399776 Levetiracetam Tablets 250mg Tab ACH 02399784 Levetiracetam Tablets 500mg Tab ACH 02399792 Levetiracetam Tablets 750mg Tab ACH 02296101 PMS-Levetiracetam 250mg Tab PMS 02296128 PMS-Levetiracetam 500mg Tab PMS 02296136 PMS-Levetiracetam 750mg Tab PMS 10

Drug Benefit Price (DBP) Changes DIN/PIN BRAND NAME STRENGTH DOSAGE FORM MFR DBP 02308894 Granisetron 1mg Tab AAP 9.0000 02237701 Apo-Ticlopidine 250mg Tab APX 1.0679 00481823 Rocaltrol 0.25mcg Cap HLR 0.6960 00481815 Rocaltrol 0.5mcg Cap HLR 1.1069 02382075 Mylan-Bupropion XL 150mg ER Tab MYL 0.2926 02382083 Mylan-Bupropion XL 300mg ER Tab MYL 0.5853 11

OFI Product Price Changes DIN/PIN BRAND NAME STRENGTH DOSAGE FORM MFR UNIT COST 02452693 Apo-Cinacalcet 30mg Tab APX 10.1947 02452707 Apo-Cinacalcet 60mg Tab APX 18.5900 02452715 Apo-Cinacalcet 90mg Tab APX 27.0517 12

Product Manufacturer Name Changes DIN BRAND NAME STRENGTH DOSAGE FORM CURRENT MFR NEW MFR 02247027 Keppra 250mg Tab VLH UCB 02247028 Keppra 500mg Tab VLH UCB 02247029 Keppra 750mg Tab VLH UCB 13

Product Brand and Manufacturer Name Changes DIN/PIN CURRENT BRAND NAME CURRENT MFR NEW BRAND NAME NEW MFR STRENGTH 02274183 Co Levetiracetam COB Act Levetiracetam ACV 250mg Tab 02274191 Co Levetiracetam COB Act Levetiracetam ACV 500mg Tab 02274205 Co Levetiracetam COB Act Levetiracetam ACV 750mg Tab DOSAGE FORM 14

Discontinued Products DIN/PIN BRAND NAME STRENGTH DOSAGE FORM MFR 02370816* Victrelis 200mg Cap MEK 02227444 Mylan-Cimetidine 300mg Tab MYL 02300222 Novo-Enalapril/HCTZ 5mg & 12.5mg Tab NOP 02300230 Novo-Enalapril/HCTZ 10mg & 25mg Tab NOP 02324199 Novo-Etidronatecal 400mg/500mg Tab-90 Tablets Kit NOP *Exceptional Access Program Product 15

Delisted Products DIN/PIN BRAND NAME STRENGTH DOSAGE FORM MFR 02150956 Dovonex 50mcg/g Cr LEO 02236848 Teva-Ticlopidine 250mg Tab TEV 16